Products

Tempus Pixel
Tempus (formerly Arterys)
Cardiology AI
Tempus Pixel is an AI-powered, cloud-based medical imaging analysis platform, originally by Arterys, that enhances diagnostic accuracy and workflow efficiency for radiologists and clinicians across cardiology, oncology, and neurology.

See all 1 product →

About Tempus (formerly Arterys)

Tempus is a leading healthcare technology company that leverages artificial intelligence (AI) and a vast library of multimodal data to advance precision medicine. Founded with the mission to make healthcare more data-driven, Tempus has built an operating system designed to liberate healthcare data from silos and make it actionable for physicians and researchers. This platform integrates various data modalities, including genomic sequencing, clinical records, pathology slides, and radiology images, to provide a comprehensive view of each patient.

For physicians, Tempus offers Intelligent Diagnostics that utilize AI, including generative AI, to enhance the accuracy, tailoring, and personalization of laboratory tests. The company’s AI-enabled platform contextualizes results for individual patients, aiding in personalized treatment decisions. Tempus also provides tools like ‘ONE’ for ordering and managing tests, ‘NEXT’ to identify and close gaps in care, and ‘LENS’ for researchers to analyze real-world data and build cohorts.

Tempus’s capabilities have been significantly expanded through strategic acquisitions, notably the integration of Arterys in October 2022. This acquisition brought Arterys’ AI platform for medical imaging, including FDA-cleared solutions for analyzing various scans like lung CTs, chest X-rays, and cardiac MRIs, into Tempus’s offerings. This allows for a more holistic patient view encompassing radiology images alongside molecular and clinical data, further strengthening Tempus’s role in powering drug discovery, genomic sequencing, and clinical trials.

Focus Areas

Precision medicine genomic testing oncology cardiology radiology neuropsychiatry infectious disease AI-enabled diagnostics clinical trial matching real-world data analysis digital pathology

Business Intelligence

Key InvestorsSoftBank Group, Baillie Gifford, New Enterprise Associates (NEA), Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, Ares Management, ARK Investment Management LLC, BlackRock, Inc., Vanguard Group Inc.
PartnershipsARPA-H, SoftBank (Japan JV), GSK, AstraZeneca, Predicta Biosciences, Gilead, Medtronic, Illumina, Daiichi Sankyo, IFLI
AcquisitionsArterys (2022), Highline Sciences (Feb 2022), Mpirik (Mar 2023), Ambry Genetics (Nov 2024, $600M), Deep 6 AI (Mar 2025), Paige (Aug 2025, $81.2M)
TechnologyTempus Platform (data ingestion, harmonization, structuring, diagnostic testing, AI-enabled analytics), AI operating system, generative AI, multimodal data (NGS, anatomic pathology, radiology, EHR data). Key products include Tempus ONE (AI-enabled assistant), NEXT (care pathway intelligence), LENS (real-world data analytics), ALGOS (algorithmic models), Tempus xR IVD (RNA NGS), Tempus Pixel (cardiac imaging), Tempus ECG-AF (AFib risk), Tempus ECG-Low EF (LVEF detection), TIME Trial Program, Olivia (patient app).
FDA Clearances4+ (8 from acquired Arterys) cleared products (estimated)

What Physicians Need to Know

Precision Medicine & Genomic Testing
Tempus specializes in AI-enabled precision medicine, offering comprehensive genomic profiling (DNA, RNA, liquid biopsy, hereditary, MRD testing) across oncology, cardiology, neuropsychiatry, and infectious diseases. They provide insights for therapy selection and early disease diagnosis.
AI-Enabled Diagnostics & Real-World Data
Leveraging one of the world's largest libraries of multimodal clinical and molecular data (over 8.5M de-identified research records), Tempus uses AI to transform unstructured data into actionable insights. This includes AI-enabled diagnostics for radiology (Tempus Pixel for various scans) and digital pathology (Paige Predict for tissue analysis).
Clinical Trial Matching
Tempus offers AI-powered clinical trial matching services (e.g., TIME program, Patient Query) that efficiently identify relevant trials for patients by analyzing combined clinical and molecular data, significantly improving enrollment efficiency.
Integrated Physician Platforms
Their proprietary platforms, such as Tempus Hub and Tempus One, are designed to integrate seamlessly into clinical workflows, providing physicians with real-time access to patient insights, test results, guideline-matched therapies, and collaborative tools.
Physician Tip

For physicians, Tempus stands out by offering a comprehensive, AI-driven platform that integrates molecular, clinical, pathology, and radiology data into a single view, enabling more personalized and informed treatment decisions. Utilize **Tempus Hub** for a centralized portal to order tests, review results, track biomarkers longitudinally, and identify clinical trial opportunities. Leverage **Tempus One**, their generative AI assistant, for quick, voice-enabled access to patient-specific summaries and guideline integration, reducing cognitive load during patient interactions. Explore the 'Patient Similarities' and 'Consults' features within Hub for peer collaboration and insights from similar cases. For imaging, **Tempus Pixel** provides AI-enhanced analysis for cardiology and radiology, improving diagnostic accuracy and efficiency. The 'Refresh' feature ensures you always have the latest therapeutic options and clinical trial matches based on evolving data and guidelines.

Tempus prioritizes seamless integration with existing healthcare systems, including deep **EHR integrations** (e.g., Epic, ASCO's CancerLinQ). This allows their AI-enabled tools and data to be directly accessible within clinical workflows, minimizing data silos and enhancing interoperability. The **Tempus Hub** platform is accessible on both mobile and desktop, providing flexibility for physicians to engage with patient data and insights from various devices. This integrated approach aims to embed precision medicine directly into routine clinical practice.

Products by Tempus (formerly Arterys)

1 product in the directory

Tempus Pixel
Tempus (formerly Arterys)
Cardiology AI
Tempus Pixel is an AI-powered, cloud-based medical imaging analysis platform, originally by Arterys, that enhances diagnostic accuracy and workflow efficiency for radiologists and clinicians across cardiology, oncology, and neurology.

What the Web Says

Tempus (formerly Arterys) is a company focused on AI-driven precision medicine, particularly in oncology and medical imaging. While their products, such as the AI platform for medical imaging and genomic profiling assays, are generally viewed as innovative and impactful for patient care, employee reviews paint a mixed picture of the company culture and management. There are also some concerns regarding customer service and billing practices for their testing services.

Overall: Mixed

Strengths

  • AI-enabled precision medicine and innovative technology.
  • Products aim to improve patient care and outcomes, especially in oncology.
  • Seamless integration into existing clinical tools and workflows.
  • Collaborative and intellectually stimulating work environment (reported by some employees).
  • Good benefits and PTO (reported by some employees).
  • Strong funding and clinical partnerships.

Limitations

  • Mixed to negative employee reviews regarding management and culture.
  • Poor work-life balance and employees often stretched thin.
  • Low pay and benefits, including no 401K matching (reported by some employees).
  • Lack of job security and advancement opportunities, with promotions based on tenure rather than merit.
  • Customer service issues, including unresponsiveness and billing problems.
  • Disorganization and lack of transparency from management.

Based on reviews from: Indeed.com, Tempus.com, Spotsaas.com, SoftwareWorld.com, AIToolsBox.com, Nebula Genomics, Trustpilot.com, G2.com, Reddit.com, Capterra.com, Slashdot.org, JobzMall.com, BuiltIn.com, AI Suggests, Dennis Gong

Last updated: 2026-07-17

Videos

News, demos, and interviews about Tempus (formerly Arterys).

Loading videos...

Videos load interactively. If none appear, search YouTube for Tempus (formerly Arterys) →

View all on YouTube

Press & Coverage

Fierce Healthcare
With Arterys acquisition under its belt, Tempus eyes big opportunities in medical imaging AI
Tempus acquired medical imaging AI developer Arterys in October 2022, a move that significantly expands Tempus' capabilities in radiology and pathology-based AI applications. This acquisition integrates Arterys' FDA-approved technology platform, which includes eight FDA-cleared algorithms for imaging in neurology, oncology, and cardiology, into Tempus' offerings.
2023-02
AI Forum
Tempus Announces $275 Million in Funding
Tempus announced $275 million in additional funding in October 2022, through a combination of equity and debt financing. This funding brings Tempus' total raised to over $1.3 billion, and it will be used to scale operations and capabilities, focusing on its disease-agnostic platform.
2022-10
Business Wire
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Tempus received FDA 510(k) clearance in September 2025 for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update enables the generation of T1 and T2 inline maps for cardiac MR image analysis, enhancing insights into cardiac health.
2025-09
Tempus AI News
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus announced the successful multi-center validation of its FDA-cleared ECG-AF software for predicting the one-year risk of atrial fibrillation, with results published in Heart Rhythm. This study highlights the potential of AI to shift cardiac care towards earlier risk detection.
2026-06
Business Wire
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
Tempus announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform, in May 2026. This upgrade introduces advanced generative AI clinical co-pilot capabilities directly into the Hub to streamline clinical workflows and provide on-demand decision support.
2026-05
Business Wire
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Tempus highlighted the results of the Articulate Pro study, published in Nature Digital Medicine in July 2026, which evaluated the use of AI to assist pathologists in prostate biopsy reporting. The study demonstrated that AI-assisted review supported pathologists in re-assessing and updating diagnoses for 5% of patients.
2026-07
Business Wire
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
Tempus announced a significant expansion of new indications to its AI-enabled Next platform in May 2026, ahead of the ASCO Annual Meeting. This platform aims to deliver real-time clinical intelligence and close critical care gaps in oncology by analyzing unstructured EHR data.
2026-05
Fierce Healthcare
Precision medicine company Tempus AI aims to raise $400M in IPO
Tempus AI is looking to raise as much as $410.7 million in an IPO by selling 11.1 million shares at $35 to $37 each, targeting a valuation of up to $6.10 billion. The company has expanded its AI-enabled patient data platform into various disease categories beyond oncology.
2024-06

Frequently Asked Questions

Tempus leverages its extensive library of clinical and molecular data with AI-powered analytics to provide comprehensive genomic profiling, primarily in oncology. This integration helps physicians make data-driven treatment decisions and identify potential clinical trial matches for patients.
While strong in oncology, Tempus is expanding its AI-enabled diagnostic solutions to cardiology, neuropsychiatry, and infectious disease. The acquisition of Arterys significantly bolstered its capabilities in AI-powered radiology diagnostics, offering advanced imaging analysis for areas like neurology, oncology, and cardiology with eight FDA-approved algorithms.
Tempus aggregates a vast library of de-identified real-world clinical and molecular data, which AI analyzes to identify patterns and therapeutic avenues. This robust data infrastructure, combined with advanced trial matching services, powers their clinical trial matching platform, connecting eligible patients with relevant studies more efficiently.
Tempus provides AI-enabled digital pathology solutions, such as Paige Predict, that assist pathologists in identifying biomarkers and disease characteristics, enhancing diagnostic precision and optimizing tissue use. The company adheres to strict data privacy regulations like HIPAA and employs rigorous validation processes for its AI algorithms to ensure accuracy and reliability.
Tempus prioritizes data security and compliance, maintaining robust safeguards and adhering to all relevant healthcare regulations, including HIPAA, for patient data and genomic information. Integration typically involves secure data exchange protocols and can be tailored to fit various EHR systems and clinical workflows, aiming for seamless incorporation into existing practices.
Tempus's pricing models for services like genomic testing panels or data analytics subscriptions are generally discussed directly with institutions, with genomic tests typically ranging from $2,500-$4,000. They offer dedicated clinical support teams and actively seek partnerships with healthcare systems and researchers to advance precision medicine.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare fintech company that leverages AI and automation to address the growing challenge of healthcare affordability for patients and financial stability for providers. The platform offers personalized, interest-free payment plans, extending up to 60 months, tailored to each patient’s ability to pay. This approach aims to remove financial barriers to care, allowing […]

Healthcare Finance.AI is dedicated to optimizing healthcare revenue cycles through cutting-edge AI technologies. The company aims to improve financial outcomes for healthcare providers while supporting their commitment to quality care and efficiency. Their solutions are designed to enhance revenue cycle efficiency, reduce claim turnaround times, and improve patient billing accuracy. Their platform leverages advanced analytics […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School, a faculty of Imperial College London, is a leading institution that integrates business education with science, engineering, medicine, and technology. For physicians and healthcare providers, the Business School offers specialized programs and research focused on the intersection of AI, digital transformation, and healthcare management. Their curriculum is designed to equip healthcare […]

Columbia University, through its online learning platform edX, offers a range of educational programs, including those focused on artificial intelligence and its applications in healthcare. While not a direct AI product company, Columbia University provides foundational and advanced courses that equip physicians and healthcare providers with the knowledge and skills to understand, evaluate, and potentially […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.